Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), andthe KXL® system, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive
keratoconus and corneal ectasia following refractive surgery.*1

Your key to topography:

The iDetect KC program
Keratoconus care starts with you

iDetect KC puts advanced topography into your practice so you can:• Quickly and easily take the lead in identifying keratoconus earlier• Offer FDA-approved treatments to manage, slow, or halt disease progression• Provide lifelong care and expertise for your patients70%

OF KERATOCONUS PRESENTS THROUGH
OPTOMETRY, UNDERSCORING THE
CRITICAL ROLE OF OPTOMETRISTS IN
IDENTIFICATION AND TREATMENT.2

Evidence suggests more patients could
benefit from earlier keratoconus detection
Onset: The vast majority of cases present
between 12 and 20 years of age. Onset may
also occur at birth and up to 51 years of age.3
Early detection is critical: In one study,
70% of eyes had reached topographic
keratoconus classification stage 2 orhigher by the time of diagnosis. Only 13%of patients were diagnosed before age 18.4

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® system is manufactured by Avedro. Avedro is a Glaukos company.
PM-US-1276 Rev. 2

Putting the power oftrusted topography into practice
A paradigm shift
in your diagnostic accuracy
Advanced topography aids in the diagnosis of keratoconus and disease progression monitoring,ensuring greater confidence in your assessments.

in your keratoconus management approach
iDetect KC enables you to simplify the diagnostic and treatment journey and retain greater control
over the patient experience.

iDetect KC enables you to integrate the 3 pillars of modern
keratoconus care into your practice:
Early diagnosis and monitoring: Identify patients sooner and monitor them for progression
with advanced topography so you can help preserve their vision with earlier intervention.

Slow or halt progression: Refer out to an ophthalmologist to perform cross-linking with the
only FDA-approved treatment option for progressive keratoconus.
Only iLink®:• Addresses the underlying pathophysiology of progressive keratoconus• Slows or halts progressive keratoconus with proven technology, efficacy, and safety• Is eligible for commercial insurance coverage, with over 95% of commercially covered lives

Patient retention: Topography enables you to provide long-term, continued medical care foryour patients and supports the expansion of your contact lens service.

Optimizing outcomes with
next-level keratoconus care

Glaukos and Topcon have partnered to offer you advanced topography technology for easy
and early keratoconus diagnosis at a lower cost of entry.

The Topcon CA-800 Topographer
Key features and benefits5• Placido-based topography delivers complete anterior corneal surface evaluation for early detection• Advanced keratoconus probability index indicates keratoconus likelihood through analysis of apicalcurvature, apical gradient, and symmetry of the cornea• Easy serial follow-up on keratoconus and keratoconus-like patterns• Diagnostic capabilities for various common ocular pathologies, including detailed dry eye measurements

Simplify
Keratoconus Diagnosis
The Topcon CA-800 is designed to give you
the full picture of your patient’s corneal
topography and simplify diagnosis by:• Measuring keratoconus-specific parameters• Providing a keratoconus probability index (KPI)
percentage• Delivering results in an intuitive, color-coded
format- Green, yellow, and red indicate the degreeof compatibility with keratoconus

ONLY$12,000 FROM A LIST PRICE OF $14,790

iDetect KC allows you to advance your practice for a fraction of the price and offers:• Inclusion of a second-year warranty valued at $1,900• Financing availability
For more information,visit topconhealthcare.com.
PM-US-1276 Rev. 2

PM-US-1276 Rev. 2

Technology that keeps on giving
The benefits of choosing the iDetect KC program are vast and lifelong

A win forConfident diagnosis of keratoconus and the only
FDA-approved treatment for slowing or halting diseaseprogression from the optometrist they know and trust.

A win forComprehensive care for your progressive keratoconus
patients through diagnosis, intervention, and longterm follow-up.

A win for

Simplified keratoconus screening with advanced
topography that delivers results in aneasy-to-understand format.

patients
eye careyour practice

By confirming a progressive keratoconus diagnosis sooner, you canhelp preserve patients’ vision by providing them with treatment
options, including iLink®—the only FDA-approved cross-linking
treatment for the condition.
For more information on bringing an advanced topographer into your optometry practice, visit
Glaukos.com/contact-us, email us at idetectkc@glaukos.com, or contact your Glaukos representative.

REFERENCES
1. Photrexa. Package insert. Waltham, MA: Glaukos, Inc; 2016.
2. Eisenberg JS. First treatment for keratoconus itself. Optometry Times. June 1, 2012. Accessed September 30, 2020. https://www.optometrytimes.com/view/first-treatment-keratoconus-itself
3. Valdez-Garcia JE, Supúlveda R, Salazar-Martínez JJ, Lozano-Ramírez JF, Prevalence of keratoconus in an adolescent population. Revista Mexicana de Oftalmologia. 2014;88:95-98.
4. Kreps EO, Claerhout I, Koppen C. Diagnostic patterns in keratoconus. Cont Lens Anterior Eye. 2021;44(3):101333.
5. CA-800 Corneal Analyzer. Topcon Medical Systems Inc; 2017.
INDICATIONS
Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagencross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.
Corneal collagen cross-linking should not be performed on pregnant women.
IMPORTANT SAFETY INFORMATION
Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.
The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced
visual acuity, and blurred vision.
These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

PM-US-1276 Rev. 2Glaukos® and iLink® are registered trademarks of Glaukos Corporation. Photrexa®, Photrexa® Viscous, and theKXL® system are registered trademarks of Avedro, a Glaukos company. All rights reserved. ©2023

San Clemente, CA +1-949-367-9600